Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Domestic drug pricing agreement

Trump announces nine new drug pricing deals

Analysis based on 38 articles · First reported Aug 18, 2026 · Last updated Sep 04, 2026

Sentiment
40
Attention
6
Articles
38
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The agreements are expected to lower drug prices for U.S. patients and reduce government spending, potentially pressuring pharmaceutical revenues but improving affordability and access. The deals provide tariff relief and regulatory certainty for participating companies, while the broader drug pricing environment remains influenced by the Inflation Reduction Act and market competition.

Pharmaceuticals Healthcare Biotechnology

On August 31, 2026, President Donald Trump announced voluntary drug pricing agreements with nine pharmaceutical companies: Alcon, Astellas Pharma, BeOne Medicines, BridgeBio Pharma, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. These companies agreed to offer most-favored-nation (MFN) pricing to U.S. United States — Medicaid programs and for future innovative medicines, in exchange for tariff relief and exemption from Section 232 pharmaceutical tariffs. The deals bring the total number of MFN agreements to 26, covering about 89% of the branded drug market, and are projected to save Americans over $600 billion over 10 years, according to Trump. The announcement follows earlier agreements with 17 large drugmakers including Pfizer, Eli Lilly, and Amgen. Concurrently, the United States — White House touted a 0.8% decline in prescription drug prices in July, the largest annual drop since 1963, attributing it to these deals and the TrumpRx website. However, drug pricing experts note that other factors, including the Biden-era Inflation Reduction Act's Medicare negotiation provisions and increased generic/biosimilar competition, likely contributed more significantly. The actual impact of the MFN deals remains unclear as contracts are not public and models are not yet implemented. BeOne Medicines separately announced a $300 million onshoring investment in New Jersey, bringing its total U.S. manufacturing investment to over $1 billion. Sun Pharma's agreement also delays potential Section 232 tariffs for over two years, supporting its planned $11.75 billion acquisition of Organon & Co..

90 United States expanded drug pricing program
90 Donald Trump announced drug pricing deals
87 Sun Pharma announced acquisition Organon & Co.
85 BeOne Medicines signed drug pricing deal United States
80 Astellas Pharma signed drug pricing deal United States
80 CSL Limited signed drug pricing deal United States
80 BridgeBio Pharma signed drug pricing deal United States
80 Sun Pharma signed drug pricing deal United States
80 UCB signed drug pricing deal United States
80 Alcon signed drug pricing deal United States
80 Kyowa Kirin signed drug pricing deal United States
80 BeOne Medicines announced investment
70 Donald Trump signed agreements
70 Donald Trump announced agreements United States
70 United States — Medicare negotiated drug prices
+ 10 more actions View on Dashboard
cnt
The U.S. government, through the United States — White House, negotiated the drug pricing deals to lower costs for patients and reduce federal spending. The agreements are part of a broader push to make healthcare more affordable.
Importance 100.0 Sentiment 60.0
per
President Trump announced the new drug pricing deals, taking credit for declining drug prices. The agreements bolster his administration's healthcare affordability agenda ahead of midterm elections.
Importance 100.0 Sentiment 60.0
govactor
The United States — White House hosted the announcement and promoted the deals as delivering savings. It also launched the TrumpRx website and touted declining drug prices, though experts question the attribution.
Importance 90.0 Sentiment 60.0
govactor
United States — Medicaid programs will benefit from MFN pricing, potentially saving billions in taxpayer dollars. The agreements ensure lower drug costs for beneficiaries.
Importance 80.0 Sentiment 70.0
priv
BeOne Medicines agreed to provide an oncology medicine at reduced United States — Medicaid pricing and committed to $11 billion U.S. investment through 2029. It also announced a $300 million onshoring investment in New Jersey, enhancing its U.S. manufacturing footprint.
Importance 70.0 Sentiment 50.0
stock
Sun Pharma extended MFN pricing to United States — Medicaid and future launches, gaining a two-year tariff reprieve. The deal supports its planned $11.75 billion acquisition of Organon & Co., though shares dipped about 1%.
Importance 70.0 Sentiment 45.0
govactor
CMS, led by Mehmet Oz, is involved in implementing the drug pricing deals and overseeing United States — Medicaid programs.
Importance 60.0 Sentiment 10.0
stock
Alcon agreed to MFN pricing for United States — Medicaid and future innovative medicines, gaining tariff relief. This may reduce U.S. revenue but improves market access and regulatory certainty.
Importance 60.0 Sentiment 40.0
stock
Astellas signed a drug pricing deal, extending MFN pricing to United States — Medicaid. This aligns with its earlier participation and may impact U.S. pricing but secures tariff exemptions.
Importance 60.0 Sentiment 40.0
stock
BridgeBio Pharma joined the MFN pricing agreement, offering drugs at reduced prices to United States — Medicaid. This may lower U.S. revenue but provides tariff relief and supports patient access.
Importance 60.0 Sentiment 40.0
stock
CSL signed the drug pricing deal, committing to MFN pricing for United States — Medicaid and future products. This could affect U.S. sales but secures tariff exemptions.
Importance 60.0 Sentiment 40.0
stock
Kyowa Kirin agreed to MFN pricing and plans to increase U.S. manufacturing, aiming to supply over 95% of its U.S.-manufactured drugs to American patients within two years.
Importance 60.0 Sentiment 40.0
stock
UCB joined the MFN pricing agreement, offering drugs at reduced prices to United States — Medicaid. This could impact U.S. sales but secures tariff exemptions.
Importance 60.0 Sentiment 40.0
stock
Novo Nordisk was among the earlier 17 companies that signed drug pricing deals, part of the broader initiative.
Importance 50.0 Sentiment 0.0
govactor
United States — Medicare is affected by the drug pricing negotiations and the new MFN deals, which aim to lower costs for beneficiaries. The administration's policies, including GLP-1 price reductions, may also impact United States — Medicare spending.
Importance 50.0 Sentiment 20.0
+ 17 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.